Five conditions. One usable pathway.
A backup product is not yet a continuity plan.
Human judgment governs the pathway.
The five conditions organize the evidence for a decision. People with the relevant expertise and authority weigh that evidence in context, set priorities, and authorize action. They remain accountable for the outcome.
Human judgment leads. Intelligence informs. Accountable people decide.
The FDA’s October 5 update on certain BD Alaris infusion sets makes the distinction clear. Its recommendations address clinically appropriate alternatives, prioritization when quantities are limited, and circumstances in which different pumping equipment may be needed. FDA recall communication.
That is constrained continuity in practice.
The question is not simply, “Do we have an approved alternative?”
It is:
- Is it qualified for this use?
- How much usable inventory exists, and where?
- How long will deployment take?
- Does it fit the equipment, people and operating conditions?
- Who can authorize the change—and allocate supply if there is not enough?
A supplier record, catalog number or signed agreement cannot establish all of that by itself.
Advance notice helps, but it only creates an opportunity to act. In a separate September 22 warning letter to Unilam, the FDA identified missing supplier change-notification agreements and the resulting loss of an opportunity to assess requalification or updated testing before distribution. FDA warning letter.
Notification begins the continuity work. It does not complete it.
A usable backup pathway brings five conditions together: qualified use, available quantity, deployment time, operational fit and release authority.
If one is unresolved, the organization may have an alternative on paper while still facing an allocation decision where the product is needed.
An alternate is not yet capacity.
Source note: Both FDA pages were checked October 16, 2026. The recall communication concerns specified devices and use cases; the Unilam letter concerns a separate manufacturer and product category. The five-condition framework is SUCH editorial analysis, not an FDA standard. This essay does not prescribe clinical use, assess a facility’s response or claim that SUCH supplied either product.
Explore Signal